Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity

mTOR inhibition can promote or inhibit immune responses in a context dependent manner, but whether this will represent a net benefit or be contraindicated in the context of immunooncology therapies is less understood. Here, we report that the mTORC1/2 dual kinase inhibitor vistusertib (AZD2014) pote...

Descripción completa

Detalles Bibliográficos
Autores principales: Langdon, Sophie, Hughes, Adina, Taylor, Molly A., Kuczynski, Elizabeth A., Mele, Deanna A., Delpuech, Oona, Jarvis, Laura, Staniszewska, Anna, Cosulich, Sabina, Carnevalli, Larissa S., Sinclair, Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136876/
https://www.ncbi.nlm.nih.gov/pubmed/30221055
http://dx.doi.org/10.1080/2162402X.2018.1458810

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136876/
https://www.ncbi.nlm.nih.gov/pubmed/30221055
http://dx.doi.org/10.1080/2162402X.2018.1458810

Ejemplares similares